… EGFR mutations in lung cancer and to develop a sensitive method for rapid screening of
mutations… large series of consecutive NSCLC patients for EGFR mutations in exons 18, 19, and …

… L858R EGFR mutants, as compared with wild-type EGFR in … -type EGFR or heterozygous
activating mutations in EGFR, … to lung cancer cells in which EGFR mutations appear to drive …

… The discovery of EGFR tyrosine kinase inhibitors (TKI) was regarded as a landmark finding
… of lung cancer [5–8]. Targeted EGFR-TKI first-line treatment of sensitizing EGFR mutations …

… (EGFR) mutations in NSCLC launched the era of personalized medicine in advanced Non
Small Cell Lung Cancer (… of activating mutations in the tyrosine kinase domain of the EGFR in …

… PF00299804, an irreversible pan ErbB inhibitor, is effective in lung cancer models with
EGFR and HER2 mutations that are resistant to gefitinib. Cancer Res 67: 11924–11932. …

… for lung cancer patients with an EGFR mutation. In this review, we describe the features
of KRAS mutations in lung cancer and contrast these with the features of EGFR mutations. …

… discovery of EGFR mutations in non-small cell lung cancers have resulted in a considerable
amount of research and publication in this area. To date, EGFR mutation analysis by direct …

… In conclusion, screening for EGFR mutations is warranted in women with lung cancer, in
those who have never smoked, and in those with nonsquamous tumors. Large-scale screening …

… mutations. To develop a … of EGFR mutations in NSCLC patients, we generated mutation-specific
rabbit monoclonal antibodies against each of these two most common EGFR mutations …

… mutations in the epidermal growth factor receptor (EGFR) are present in ∼10% of nonsmall
cell lung cancers… Small in‐frame deletions in exon 19 (∼45%) and L858R mutation in exon …